## Rafael Ochoa-Sanchez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9623657/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genetically engineered <i>E. coli</i> Nissle attenuates hyperammonemia and prevents memory impairment in bileâ€duct ligated rats. Liver International, 2021, 41, 1020-1032.	1.9	10
2	Hepatic Encephalopathy: From Metabolic to Neurodegenerative. Neurochemical Research, 2021, 46, 2612-2625.	1.6	21
3	Dysfunction of serotonergic activity and emotional responses across the lightâ€dark cycle in mice lackingÂmelatonin MT <sub>2</sub> receptors. Journal of Pineal Research, 2020, 69, e12653.	3.4	17
4	An Investigation of PSâ€ <i>b</i> â€PEO Polymersomes for the Oral Treatment and Diagnosis of Hyperammonemia. Small, 2019, 15, e1902347.	5.2	22
5	P: 83 Obesity Accelerates and Exacerbates Neurological Impairments Associated to Hepatic Encephalopathy in Chronic Liver Disease. American Journal of Gastroenterology, 2019, 114, S40-S40.	0.2	Ο
6	P: 82 Genetically Engineered E. coli Nissle Attenuates Hyperammonemia and Improves Memory in an Experimental Model of Cirrhosis and Hepatic Encephalopathy. American Journal of Gastroenterology, 2019, 114, S39-S40.	0.2	0
7	P: 50 Developing a New Animal Model of Episodic Hepatic Encephalopathy. American Journal of Gastroenterology, 2019, 114, S25-S26.	0.2	0
8	Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain, 2019, 160, 136-150.	2.0	239
9	Progressive resistance training prevents loss of muscle mass and strength in bile ductâ€ligated rats. Liver International, 2019, 39, 676-683.	1.9	10
10	Pathogenesis of Hepatic Encephalopathy in Chronic Liver Disease. Journal of Clinical and Experimental Hepatology, 2018, 8, 262-271.	0.4	50
11	Development of a New Animal Model of Obesity and Chronic Liver Disease for the Study of Hepatic Encephalopathy. Journal of Clinical and Experimental Hepatology, 2017, 7, S60.	0.4	0
12	Effects of Anaerobic Exercise in Muscle Strength and Muscle Mass Optimization in Bile Duct Ligated Rats. Journal of Clinical and Experimental Hepatology, 2017, 7, S82-S83.	0.4	0
13	The bile duct ligated rat: A relevant model to study muscle mass loss in cirrhosis. Metabolic Brain Disease, 2017, 32, 513-518.	1.4	30
14	The hallucinogen d -lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT 1A , D 2 and TAAR 1 receptors. Pharmacological Research, 2016, 113, 81-91.	3.1	76
15	Melancholic-Like Behaviors and Circadian Neurobiological Abnormalities in Melatonin MT1 Receptor Knockout Mice. International Journal of Neuropsychopharmacology, 2015, 18, pyu075-pyu075.	1.0	56
16	Melatonin, selective and non-selective MT1/MT2 receptors agonists: Differential effects on the 24-h vigilance states. Neuroscience Letters, 2014, 561, 156-161.	1.0	27
17	Reduction in cholinergic interneuron density in the nucleus accumbens attenuates local extracellular dopamine release in response to stress or amphetamine. Synapse, 2013, 67, 21-29.	0.6	12
18	Sleep–wake characterization of double MT1/MT2 receptor knockout mice and comparison with MT1 and MT2 receptor knockout mice. Behavioural Brain Research, 2013, 243, 231-238.	1.2	95

#	Article	IF	CITATIONS
19	Short-term effects of melatonin and pinealectomy on serotonergic neuronal activity across the light–dark cycle. Journal of Psychopharmacology, 2012, 26, 830-844.	2.0	30
20	Adolescent amphetamine exposure elicits dose-specific effects on monoaminergic neurotransmission and behaviour in adulthood. International Journal of Neuropsychopharmacology, 2012, 15, 1319-1330.	1.0	29
21	Anxiolytic effects of the melatonin MT2 receptor partial agonist UCM765: Comparison with melatonin and diazepam. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 318-325.	2.5	60
22	Promotion of Non-Rapid Eye Movement Sleep and Activation of Reticular Thalamic Neurons by a Novel MT <sub>2</sub> Melatonin Receptor Ligand. Journal of Neuroscience, 2011, 31, 18439-18452.	1.7	113
23	M-B-035 SLEEP IN MT2 MELATONIN RECEPTOR KNOCKOUT MICE. Sleep Medicine, 2011, 12, S32.	0.8	0